We can't find the internet
Attempting to reconnect
18018.2 PFLS-LS
Preclinical development of a new drug for cognitive disorders including Alzheimer¿s disease
Résumé
Preclinical development of a new drug for cognitive disorders including Alzheimer¿s disease
Textes supplémentaires
Abstract
The CTI project 13875.1 PFLS-LS lead to the discovery of compounds HiQ0013 specific for the á7 neuronal nicotinic acetylcholine receptor and HiQ0025 which is specific for the á3â2|subtype. HiQ0013 a partial agonist at á7 enhances the response to acetylcholine at concentration in the nanomolar range. HiQ0013 was found to be active in rodents and in aged monkeys. The aim of this project is to complete preclinical testing and to consolidate data obtained at backup candidates.
Participants
Daniel Bertrand
Wirtschaftspartner
daniel.bertrand@hiqscreen.com
HiQScreen SàRL Daniel Bertrand Route de Compois 6 1222 Vésenaz GE CH
Jean-Louis Reymond
Kontaktperson
reymond@ioc.unibe.ch
Universität Bern Department of Chemistry and Biochem Jean-Louis Reymond Freiestrasse 3 3012 Bern BE CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2016-04-30
- Date de fin
- 2018-04-30
- Coûts totaux approuvés
- CHF 190000.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T490 Biotechnology 100.0%